Document is current
Any future updates will be listed below
-
Authors
Dhurandhar, Emily J. https://orcid.org/0000-0001-7633-5083
Maki, Kevin C.
Dhurandhar, Nikhil V. https://orcid.org/0000-0002-1356-1064
Kyle, Theodore K. https://orcid.org/0000-0003-1119-5854
Yurkow, Sydney
Hawkins, Misty A. W.
Agley, Jon
Ho, Emily H. https://orcid.org/0000-0002-3522-3779
Cheskin, Lawrence J. https://orcid.org/0000-0003-0262-1030
Sørensen, Thorkild I. A. https://orcid.org/0000-0003-4821-430X
Wang, Xi Rita
Allison, David B. https://orcid.org/0000-0003-3566-9399
- License Information
-
More Information
Article History
Received: 16 January 2025
Revised: 19 May 2025
Accepted: 23 May 2025
First Online: 8 July 2025
Competing interests
: Emily Dhurandhar receives consulting fees as Chief Scientific Officer of Obthera. In the last thirty-six months, Dr. Allison has received personal payments or promises for same from: Novo Nordisk Foundation; Roman Health Ventures, LLC; Sand Zero Longevity Science (as stock options). Dr. Allison’s institution, Indiana University, and the Indiana University Foundation have received funds or donations to support his research or educational activities from: Eli Lilly and Company; Roman Health Ventures, LLC; WW (formerly Weight Watchers); and numerous other for-profit and non-profit organizations to support the work of the School of Public Health and the university more broadly. Lawrence J. Cheskin serves as an advisor and has equity in Aardvark Therapeutics. Kevin C. Maki has received research grant support and/or consulting fees during the prior 36 months related to body weight and appetite regulation from Cargill, Eli Lilly, General Mills, Novo Nordisk, and the National Cattlemen’s Beef Association. No other authors have disclosures related to this work.
